サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：補体標的治療薬の世界市場規模：適応症別（発作性夜間血色素尿症、非定型溶血性尿毒症症候群）、流通チャネル別、地域別予測（2022年～2028年）
市場調査レポート
商品コード
1090045

補体標的治療薬の世界市場規模：適応症別（発作性夜間血色素尿症、非定型溶血性尿毒症症候群）、流通チャネル別、地域別予測（2022年～2028年）

Global Complement-targeted Therapeutics Market Size study, By Indication (Paroxysmal Nocturnal Haemoglobinuria, Atypical Haemolytic Uraemic Syndrome ), By Distribution Channel, and Regional Forecasts 2022-2028
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
補体標的治療薬の世界市場規模：適応症別（発作性夜間血色素尿症、非定型溶血性尿毒症症候群）、流通チャネル別、地域別予測（2022年～2028年）
出版日: 2022年06月09日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の補体標的治療薬の市場規模は、慢性疾患の増加、補体標的治療薬の臨床研究の増加、最近の共同研究活動、免疫系疾患の有病率の増加、新興国における医療インフラの整備などによって促進されています。

一方で、補体欠乏症に対する認識不足と高い治療費が、予測期間における同市場の成長を阻害すると予想されています。

当レポートでは、世界の補体標的治療薬市場を調査しており、市場の概要、市場分析、適応症・流通チャネル・地域別の分析、および競合情勢など、包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の補体標的治療薬市場の定義と範囲

第3章 世界の補体標的治療薬市場力学

  • 補体標的治療薬市場の影響分析（2020年～2028年）

第4章 世界の補体標的治療薬市場の業界分析

  • ポーターのファイブフォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論
  • 主要投資機会
  • 主要成功戦略

第5章 リスク評価：COVID-19の影響

    • 業界に対するCOVID-19の全体的な影響の評価
    • COVID-19以前およびCOVID-19後の市場シナリオ

第6章 世界の補体標的治療薬市場：適応症別

  • 市場スナップショット
  • 適応症別の世界の補体標的治療薬市場の実績-潜在性分析
  • 適応症別の世界の補体標的治療薬市場の推定と予測（2018年～2028年）
  • 補体標的治療薬市場、サブセグメント分析
    • 発作性夜間血色素尿症
    • 非定型溶血性尿毒症症候群（Ahus）

第7章 世界の補体標的治療薬市場：流通チャネル別

  • 市場スナップショット
  • 流通チャネル別の世界の補体標的治療薬市場の実績-潜在性分析
  • 流通チャネル別の世界の補体標的治療薬市場の推定と予測（2018年～2028年）
  • 補体標的治療薬市場、サブセグメント分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第8章 世界の補体標的治療薬市場：地域別

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋
  • ラテンアメリカスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第9章 競合情報

  • 主要市場戦略
  • 企業プロファイル
    • Creative Biolabs
    • Complement UK
    • Novartis Ag
    • Alexion Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Allergan Plc.
    • Abbvie
    • Sino Biological Inc.
    • Cascade Biotechnology Inc.

第10章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Complement-targeted Therapeutics Market, report scope
  • TABLE 2. Global Complement-targeted Therapeutics Market estimates & forecasts by Region 2018-2028 (USD Million)
  • TABLE 3. Global Complement-targeted Therapeutics Market estimates & forecasts by Indication 2018-2028 (USD Million)
  • TABLE 4. Global Complement-targeted Therapeutics Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)
  • TABLE 5. Global Complement-targeted Therapeutics Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 6. Global Complement-targeted Therapeutics Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 7. Global Complement-targeted Therapeutics Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 8. Global Complement-targeted Therapeutics Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 9. Global Complement-targeted Therapeutics Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 10. Global Complement-targeted Therapeutics Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 11. Global Complement-targeted Therapeutics Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 12. Global Complement-targeted Therapeutics Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 13. Global Complement-targeted Therapeutics Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 14. Global Complement-targeted Therapeutics Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 15. U.S. Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 16. U.S. Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 17. U.S. Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 18. Canada Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 19. Canada Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 20. Canada Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 21. UK Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 22. UK Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 23. UK Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 24. Germany Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 25. Germany Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 26. Germany Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 27. RoE Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 28. RoE Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 29. RoE Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 30. China Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 31. China Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 32. China Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 33. India Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 34. India Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 35. India Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 36. Japan Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 37. Japan Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 38. Japan Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 39. RoAPAC Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 40. RoAPAC Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 41. RoAPAC Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 42. Brazil Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 43. Brazil Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 44. Brazil Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 45. Mexico Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 46. Mexico Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 47. Mexico Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 48. RoLA Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 49. RoLA Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 50. RoLA Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 51. Row Complement-targeted Therapeutics Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 52. Row Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 53. Row Complement-targeted Therapeutics Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 54. List of secondary sources, used in the study of global Complement-targeted Therapeutics Market
  • TABLE 55. List of primary sources, used in the study of global Complement-targeted Therapeutics Market
  • TABLE 56. Years considered for the study
  • TABLE 57. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Complement-targeted Therapeutics Market, research methodology
  • FIG 2. Global Complement-targeted Therapeutics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Complement-targeted Therapeutics Market, key trends 2021
  • FIG 5. Global Complement-targeted Therapeutics Market, growth prospects 2022-2028
  • FIG 6. Global Complement-targeted Therapeutics Market, porters 5 force model
  • FIG 7. Global Complement-targeted Therapeutics Market, pest analysis
  • FIG 8. Global Complement-targeted Therapeutics Market, value chain analysis
  • FIG 9. Global Complement-targeted Therapeutics Market by segment, 2018 & 2028 (USD Million)
  • FIG 10. Global Complement-targeted Therapeutics Market by segment, 2018 & 2028 (USD Million)
  • FIG 11. Global Complement-targeted Therapeutics Market by segment, 2018 & 2028 (USD Million)
  • FIG 12. Global Complement-targeted Therapeutics Market by segment, 2018 & 2028 (USD Million)
  • FIG 13. Global Complement-targeted Therapeutics Market by segment, 2018 & 2028 (USD Million)
  • FIG 14. Global Complement-targeted Therapeutics Market, regional snapshot 2018 & 2028
  • FIG 15. North America Complement-targeted Therapeutics Market 2018 & 2028 (USD Million)
  • FIG 16. Europe Complement-targeted Therapeutics Market 2018 & 2028 (USD Million)
  • FIG 17. Asia pacific Market 2018 & 2028 (USD Million)
  • FIG 18. Latin America Complement-targeted Therapeutics Market 2018 & 2028 (USD Million)
  • FIG 19. Global Complement-targeted Therapeutics Market, company Market share analysis (2021)
目次

Global Complement-targeted Therapeutics Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Complement-targeted Therapeutics can be defined as therapeutics that modulate the complement system. The complement system, also called as complement cascade, is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, and promote inflammation, as well as attack the pathogen's cell membrane. However, Activation of the complement system results in the pathogenesis of some diseases such as cancer, rheumatic diseases, Alzheimer's disease, autoimmune diseases, age-related macular degeneration, and schizophrenia among others. The increasing incidences of chronic diseases and growing number of clinical research in complement-targeted therapeutics as well as recent collaboration activities are factors that are accelerating the global market demand. For instance, according to World Health Organization - as of 2021, globally around 41 million people lost their lives due to Noncommunicable diseases (NCDs). NCDs are accounted for around 71% of all global deaths. IN NCDs Cardiovascular diseases account for largest number of deaths, or 17.9 million deaths, followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). Furthermore, in June 2021, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. entered in a five-year research collaboration. Under this collaboration both the companies would utilize Beam's proprietary base editing technology to discover new treatments for complement-driven diseases. The companies would work together on six research programs focused on C3 and other complement targets in the eye, liver, and brain. Also, growing prevalence of immune system diseases and rising healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, lack of awareness towards complements deficiency and high treatment cost impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Complement-targeted Therapeutics market study include: Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to growing number of clinical trials and presence of leading market players in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as rising healthcare infrastructure and increasing incidences of Noncommunicable diseases in the region, would create lucrative growth prospects for the Complement-targeted Therapeutics market across the Asia Pacific region.

Major market players included in this report are:

  • Creative Biolabs
  • Complement UK
  • Novartis Ag
  • Alexion Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Allergan Plc.
  • Abbvie
  • Sino Biological Inc.
  • Cascade Biotechnology Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Indication

  • Paroxysmal Nocturnal Haemoglobinuria
  • Atypical Haemolytic Uraemic Syndrome (Ahus)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Rest of the World

Furthermore, years considered for the study are as follows:

  • Historical year - 2018, 2019, 2020
  • Base year - 2021
  • Forecast period - 2022 to 2028

Target Audience of the Global Complement-targeted Therapeutics Market in Market Study:

  • Key Consulting Companies & Advisors
  • Large, medium-sized, and small enterprises
  • Venture capitalists
  • Value-Added Resellers (VARs)
  • Third-party knowledge providers
  • Investment bankers
  • Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
    • 1.2.1. Global Complement-targeted Therapeutics Market, by Region, 2020-2028 (USD Million)
    • 1.2.2. Global Complement-targeted Therapeutics Market, by Indication, 2020-2028 (USD Million)
    • 1.2.3. Global Complement-targeted Therapeutics Market, by Distribution Channel, 2020-2028 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Complement-targeted Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Complement-targeted Therapeutics Market Dynamics

  • 3.1. Complement-targeted Therapeutics Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidences of chronic diseases.
      • 3.1.1.2. Growing number of clinical research in complement-targeted therapeutics.
      • 3.1.1.3. Recent collaboration activities.
    • 3.1.2. Market Challenges
      • 3.1.2.1. Lack of awareness towards complement deficiency.
      • 3.1.2.2. High treatment cost.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing prevalence of immune system diseases
      • 3.1.3.2. Rising healthcare infrastructure in emerging economies.

Chapter 4. Global Complement-targeted Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Complement-targeted Therapeutics Market, by Indication

  • 6.1. Market Snapshot
  • 6.2. Global Complement-targeted Therapeutics Market by Indication, Performance - Potential Analysis
  • 6.3. Global Complement-targeted Therapeutics Market Estimates & Forecasts by Indication 2018-2028 (USD Million)
  • 6.4. Complement-targeted Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Paroxysmal Nocturnal Haemoglobinuria
    • 6.4.2. Atypical Haemolytic Uraemic Syndrome (Ahus)

Chapter 7. Global Complement-targeted Therapeutics Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Complement-targeted Therapeutics Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Complement-targeted Therapeutics Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)
  • 7.4. Complement-targeted Therapeutics Market, Sub Segment Analysis
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies

Chapter 8. Global Complement-targeted Therapeutics Market, Regional Analysis

  • 8.1. Complement-targeted Therapeutics Market, Regional Market Snapshot
  • 8.2. North America Complement-targeted Therapeutics Market
    • 8.2.1. U.S. Complement-targeted Therapeutics Market
      • 8.2.1.1. Indication estimates & forecasts, 2018-2028
      • 8.2.1.2. Distribution Channel estimates & forecasts, 2018-2028
    • 8.2.2. Canada Complement-targeted Therapeutics Market
  • 8.3. Europe Complement-targeted Therapeutics Market Snapshot
    • 8.3.1. U.K. Complement-targeted Therapeutics Market
    • 8.3.2. Germany Complement-targeted Therapeutics Market
    • 8.3.3. France Complement-targeted Therapeutics Market
    • 8.3.4. Spain Complement-targeted Therapeutics Market
    • 8.3.5. Italy Complement-targeted Therapeutics Market
    • 8.3.6. Rest of Europe Complement-targeted Therapeutics Market
  • 8.4. Asia-Pacific Complement-targeted Therapeutics Market Snapshot
    • 8.4.1. China Complement-targeted Therapeutics Market
    • 8.4.2. India Complement-targeted Therapeutics Market
    • 8.4.3. Japan Complement-targeted Therapeutics Market
    • 8.4.4. Australia Complement-targeted Therapeutics Market
    • 8.4.5. South Korea Complement-targeted Therapeutics Market
    • 8.4.6. Rest of Asia Pacific Complement-targeted Therapeutics Market
  • 8.5. Latin America Complement-targeted Therapeutics Market Snapshot
    • 8.5.1. Brazil Complement-targeted Therapeutics Market
    • 8.5.2. Mexico Complement-targeted Therapeutics Market
  • 8.6. Rest of The World Complement-targeted Therapeutics Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Creative Biolabs
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Complement UK
    • 9.2.3. Novartis Ag
    • 9.2.4. Alexion Pharmaceuticals, Inc.
    • 9.2.5. Merck & Co., Inc.
    • 9.2.6. Pfizer Inc.
    • 9.2.7. Allergan Plc.
    • 9.2.8. Abbvie
    • 9.2.9. Sino Biological Inc.
    • 9.2.10. Cascade Biotechnology Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption